Large Aß-peptide binding particles (LAPS) in diagnosis and therapy of Alzheimer's dementia

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides new methods for diagnosing Alzheimer's disease by measuring the concentration of particles that include both beta-amyloid (Aβ) peptides and immunoglobulins (antibodies) in patient samples, particularly in cerebrospinal fluid. The patent also describes a way to produce immunotherapy agents by purifying specific immunoglobulins from certain subtypes of these Aβ-peptide binding particles. Measuring the ratio and concentration of these molecules, especially the Aβ1-42 and Aβ1-40 forms in antibody-bound complexes, enables more accurate discrimination between Alzheimer's and non-Alzheimer's cases.

Use CasesContent extracted from patent full text and abstract with AI.

• Early and accurate diagnosis of Alzheimer's disease in patients showing symptoms of dementia.
• Differential diagnosis to distinguish Alzheimer's from other forms of dementia based on cerebrospinal fluid analysis.
• Monitoring disease progression or response to therapy in Alzheimer's patients.
• Screening for individuals at risk of developing Alzheimer's disease.
• Development of novel immunotherapy treatments targeting amyloid-beta pathology in Alzheimer's.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a more reliable and specific method for diagnosing Alzheimer's by focusing on immunoglobulin-bound amyloid-beta peptides instead of just total amyloid levels.
• Enables discrimination between Alzheimer's and non-Alzheimer dementias with higher sensitivity and less overlap between diagnostic groups.
• Potential to use less invasive samples in the future (other body fluids besides cerebrospinal fluid).
• Supports the development of targeted immunotherapy agents by identifying protective antibodies associated with resistance to Alzheimer's.
• May lead to improved early intervention and treatment outcomes due to more accurate diagnosis and monitoring.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A method of analyzing a sample obtained from a patient for indications that the patient has or is susceptible to Alzheimer's dementia comprises the step of determining at least one concentration in the sample, the at least one concentration being a concentration of A²-peptide- and immunoglobulin-including particles.